Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

NCT06072482 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT06072482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06072482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Recruiting
Start date
February 7, 2024
Completion date
December 31, 2036
Enrollment
300 (estimated)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

antineutrophil cytoplasmic antibody-associated vasculitis